You are here

Our science / Clinical Trials / Find a Trial / NCT00889603

Non-Interventional Study With Aricept® Evess

Back to Search Print Save as PDF Bookmark Trial

NCT00889603

Last updated on May 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bacau, Jud. Bacau, 600114 Romania
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer's Disease, Vascular Dementia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatients (male / female), older than 50 years.

- Patients with clinical symptoms of mild and moderate AD and Vascular Dementia.

- MMSE score between 12 - 24.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with a known hypersensitivity to donepezil clorhydrat, piperidine derivatives
or any of the excipients of Aricept® Evess.

- Patients with severe impaired hepatic function.

- Patients with pre-existing gastrointestinal ulcer disease.

- Patients with the history of bronchial asthma or chronic obstructive lung disease.

- Patients with the history of serious atrioventricular conduction disturbances.

NCT00889603
Pfizer
Completed
Non-Interventional Study With Aricept® Evess

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
2-Week Study In People With Nonalcoholic Fatty Liver Disease
NCT03513588
All Genders
18+
Years
Multiple Sites
Pneumococcal Diseases
Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey
NCT01810861
All Genders
0+
Years
Multiple Sites
Chronic Kidney Disease, Chronic Renal Failure
A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
NCT01473407
All Genders
18+
Years
Multiple Sites
Clostridium Difficile Associated Disease
Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults
NCT02725437
All Genders
65+
Years
Multiple Sites
Non-Interventional Study With Aricept® Evess
Non-Interventional Study With Aricept® Evess In Patients Diagnosed With Mild And Moderate Alzheimer's Disease Or Vascular Dementia
The Aricept® Evess study is a prospective, non-comparative, non-interventional study on use of Aricept® Evess in the treatment of out-patients with AD and Vascular Dementia. The 24 week length of the study aims to collect data from a large number of patients (n= 400) on the safety and efficacy at the usual dosage of the product providing an overview of Aricept® Evess profile.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
The patients will be selected from those addressing psychiatrists on an outpatient bases, male / female, older than 50 years, being diagnosed with Alzheimer's Disease and Vascular Dementia, with MMSE score between 12 - 24.
  • Alzheimer's Disease
  • Vascular Dementia
Drug: Aricept® Evess

5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.

Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing).
1
Intervention: Drug: Aricept® Evess
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
370
March 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Outpatients (male / female), older than 50 years.
  • Patients with clinical symptoms of mild and moderate AD and Vascular Dementia.
  • MMSE score between 12 - 24.

Exclusion Criteria:

  • Patients with a known hypersensitivity to donepezil clorhydrat, piperidine derivatives or any of the excipients of Aricept® Evess.
  • Patients with severe impaired hepatic function.
  • Patients with pre-existing gastrointestinal ulcer disease.
  • Patients with the history of bronchial asthma or chronic obstructive lung disease.
  • Patients with the history of serious atrioventricular conduction disturbances.
Sexes Eligible for Study: All
50 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Romania
 
 
NCT00889603
A2501065
Yes
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now